Asia-Pacific Inherited Retinal Diseases Market, By Disease Type (Retinitis Pigmentosa, Stargardt’s Disease, Achromatopsia, Cone-Rod Dystrophy, Choroideremia, Leber Congenital Amaurosis, Macular Edema, and Others), Type (Diagnosis and Therapy), End-Users (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, Others), Distribution Channel (Retail Sales and Direct Tender) Industry Trends and Forecast to 2029.
Market Analysis and Insights : Asia-Pacific Inherited Retinal Diseases Market
Inherited retinal diseases-or IRDs-are a group of diseases that can cause severe vision loss or even blindness. Each IRD is caused by at least one gene that is not working as it should. IRDs can affect individuals of all ages, can progress at different rates, and are rare. However, many are degenerative, which means that the symptoms of the disease will get worse over time. Common types of IRDs include Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa, Choroideremia, Stargardt’s Disease, and Achromatopsia. The goal of gene therapy is to correct or compensate for the faulty gene. IRDs are especially strong candidates for gene therapy treatments due to the retina’s unique physical makeup. Compared to other organs of the body, the eye is small and easy to access for treatment administration. However, certain areas of the body are immune privileged, which means that the normal immune response isn’t as active. This is typically in areas of our bodies that are very important and may become damaged if swelling or inflammation occurs. This means that anything that is implanted into the eye-a cell with a corrected gene, for instance-is less likely to be rejected.
The diagnosis and treatment of inherited retinal diseases consist of various techniques that allow diagnosis of inherited retinal disease after the approval of the product. The treatment for the disease is recently approved, which supports the market growth.
The inherited retinal diseases is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the inherited retinal diseases market will grow at a CAGR of 6.8% during the forecast period of 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Disease Type (Retinitis Pigmentosa, Stargardt’s Disease, Achromatopsia, Cone-Rod Dystrophy, Choroideremia, Leber Congenital Amaurosis, Macular Edema, and Others), By Type (Diagnosis and Therapy), End-Users (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, Others), Distribution Channel (Retail Sales and Direct Tender) |
|
Countries Covered |
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC) |
|
Market Players Covered |
Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson, IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies |
Inherited Retinal Diseases Market Dynamics
Drivers
- Increase in the Prevalence of Inherited Retinal Diseases
The increasing prevalence and continuous discovery of new mutagenic sites that are genetically transmitted are expected to act as a driver for the growth of the market. The prevalence of monogenic IRDs is approximately 1 in 2000, affecting two million people online.
- Increasing in Pipeline Products
As clinical trial activity rises to new levels, the field appears poised to make rapid and important advances in IRD research and patient care. These are only a few common trials, thus, the companies operating in this market continuously do clinical trials and put their candidates in clinical trials. This is expected to create an opportunity and fuel the Asia-Pacific inherited retinal diseases market.High prevalence of genetic conditions
Also, the increase in the prevalence rate of some genetic conditions such as Miller-Dieker syndrome and Walker-Warburg syndrome will further enhance the growth of the inherited retinal diseases market.
Furthermore, an increase in strategic initiatives by key players, advancement in medical technology, increasing product approval for IRDs, rising initiatives by public and private organizations to spread awareness, and growing government funding are the factors that will expand the inherited retinal diseases market. Other factors such as an increase in the demand for effective therapies and a rising adoption rate for early genetic counseling will positively impact the growth rate of the inherited retinal diseases market. Additionally, high disposable income, rising number of cases of various retinal diseases will result in the expansion of inherited retinal diseases market.
Opportunities
- Increase in Government Initiatives Towards Inherited Retinal Disease.
Moreover, the increase in awareness and treatment seeking rate and emerging reimbursement policies for the treatment will boost new opportunities for the market's growth rate.
Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the inherited retinal diseases market in the forecast period of 2022-2029. Also, the high unmet need for current treatment and developments in healthcare technology will escalate the growth rate of the inherited retinal diseases market in the future.
Restraints/Challenges
However, the high cost associated with the available treatment and lack of infrastructure in low-income countries will impede the growth rate of the inherited retinal diseases market. Additionally, lack of enough qualified professionals and complications involved with the disease will hinder the inherited retinal diseases market growth.
This inherited retinal diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Inherited retinal diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Inherited retinal disease is a genetic disorder that is relatively uncommon and whose incidence is unknown. According to a study of inherited retinal diseases the prevalence of IRD’s is 1 in 3000.
Retinitis pigmentosa is the most common disorder among the other disorders. Retinitis pigmentosa is a group of related eye disorders caused by variations in 60 genes that affect the retina. IRDs are a heterogeneous group of orphan eye diseases with a prevalence estimated at between 5 to 10%, with a Asia-Pacific IRD caseload in the range of 5–10 million individuals.
Inherited retinal diseases market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Post COVID-19 Impact on Inherited Retinal Diseases Market
The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.
Recent Development
- In January 2022, Australian Healthcare agency HSA has aaproved the Luxturna therapy for inherited retinal diseases. This will increase the revenue for the companies in the market share.
Asia-Pacific Inherited Retinal Diseases Market Scope
The inherited retinal diseases market is segmented into disease type, type, end-user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Disease Type
- Retinitis Pigmentosa
- Stargardt’s Disease
- Achromatopsia
- Cone-Rod Dystrophy
- Choroideremia
- Leber Congenital Amaurosis (LCA)
- Macular Edema
- Others
On the basis of type, the Inherited Retinal Diseasesmarket is segmented into disease type (retinitis pigmentosa, stargardt’s disease, achromatopsia, cone-rod dystrophy, choroideremia, leber congenital amaurosis, macular edema, and others), by type (diagnosis and therapy), end-users (hospitals, specialty clinics, ambulatory surgical centers, home healthcare, others), distribution channel (retail sales and direct tender.
Type
- Diagnosis
- Therapy
On the basis of type, the inherited retinal diseases market is segmented into diagnosis and therapy. The diagnosis segment is sub-segmented into gene therapy, retinal prosthetic, neuroprotective agents, others. The neuroprotective agents are further sub-segmented into vitamin A palmitate, docosahexaenoic acid (DHA), lutein, others. The diagnosis segment is segmented into clinical diagnosis and genetic diagnosis. Clinical diagnosis is further sub-segmented into retinal imaging, electrophysiological tests, visual field test and clinical eye examination. Retinal imaging is further segmented into optical coherence tomography (OCT), fundus autofluorescence imaging (FAF), scanning laser ophthalmoscopy (SLO), adaptive optics (AO) imaging and conventional color fundus imaging. Electrophysiological tests are further segmented into full-field electroretinogram (ERG) and dark adaptometry (DA). Visual field test is further segmented into computerized visual field tests and manual field test. Clinical Eye examination is segmented into slit lamp, indirect ophthalmoscopy, refraction test, dilation exam
End User
- Hospitals
- Specialty Clinics
- Ambulatory surgical center
- Home Healthcare
- Others
On the basis of end-users, the inherited retinal diseases market is segmented into hopsitals, specialty clinics, ambulatory surgical center, home healthcare and others
Distribution Channel
- Retail Sales
- Direct Tender
The inherited retinal diseases market is also segmented on the basis of distribution channel into retail sales, direct tender.
Pipeline Analysis
The pipeline analysis of inherited retinal diseases drugs includes various pipeline therapies such as NCT05244304, NCT00999609, NCT05176717, NCT05158296, NCT04850118. Belite Bio, Inc, Spark Therapeutics, ProQR Therapeutics, Applied Genetic Technologies Corp, Biogen, MeiraGTx Ltd are involved in the development of potential drugs for the improvement of treatment of seizures.
Inherited Retinal Diseases Market Regional Analysis/Insights
The inherited retinal diseases market is analysed and market size insights and trends are provided by country, disease type, type, end-user and distribution channel as referenced above.
The countries covered in the inherited retinal diseases market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC).
China dominates the inherited retinal diseases market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in this region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Asia-Pacific brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Inherited Retinal Diseases Market Share Analysis
The inherited retinal diseases market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on inherited retinal diseases market.
Some of the major players operating in the inherited retinal diseases market are Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson, IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies among others.
Research Methodology: Asia-Pacific Inherited Retinal Diseases Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report.. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Asia-PacificVsRegional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC INHERITED RETINAL DISEASES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS FOR ASIA PACIFIC INHERITED RETINAL DISEASES MARKET
5 REGULATORY FRAMEWORK
6 PREMIUM INSIGHTS
6.1 PESTEL ANALYSIS
6.2 POTER’S FIVE FORCES MODEL
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN THE PREVALENCE OF INHERITED RETINAL DISEASES
7.1.2 INCREASE IN PIPELINE PRODUCTS
7.1.3 INCREASING PRODUCT APPROVAL FOR INHERITED RETINAL DISEASES
7.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER
7.2 RESTRAINTS
7.2.1 HIGH COST OF TREATMENT AND PROCEDURES
7.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS
7.3 OPPORTUNITIES
7.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARDS INHERITED RETINAL DISEASES(IRDS)
7.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE
7.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT
7.4 CHALLENGES
7.4.1 RISKS ASSOCIATED WITH IRD SPECIFIC GENE THERAPY
7.4.2 LIMITED ACCESS TO TREATMENT
8 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE
8.1 OVERVIEW
8.2 RETINITIS PIGMENTOSA
8.3 STARGARDT’S DISEASE
8.4 ACHROMATOPSIA
8.5 CONE-ROD DYSTROPHY
8.6 CHOROIDEREMIA
8.7 LEBER CONGENITAL AMAUROSIS (LCA)
8.8 MACULAR EDEMA
8.9 OTHERS
9 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY TYPE
9.1 OVERVIEW
9.2 DIAGNOSIS
9.2.1 CLINICAL DIAGNOSIS
9.2.1.1 RETINAL IMAGING
9.2.1.1.1 OPTICAL COHERENCE TOMOGRAPHY (OCT)
9.2.1.1.2 FUNDUS AUTOFLUORESCENCE IMAGING (FAF)
9.2.1.1.3 SCANNING LASER OPHTHALMOSCOPY (SLO)
9.2.1.1.4 ADAPTIVE OPTICS (AO) IMAGING
9.2.1.1.5 CONVENTIONAL COLOR FUNDUS IMAGING
9.2.1.2 ELECTROPHYSIOLOGICAL TESTS
9.2.1.2.1 FULL-FIELD ELECTRORETINOGRAM (ERG)
9.2.1.2.2 DARK ADAPTOMETRY (DA)
9.2.1.3 VISUAL FIELD TEST
9.2.1.3.1 COMPUTERIZED VISUAL FIELD TESTS
9.2.1.3.2 MANUAL FIELD TEST
9.2.1.4 CLINICAL EYE EXAMINATION
9.2.1.4.1 SLIT LAMP
9.2.1.4.2 INDIRECT OPHTHALMOSCOPY
9.2.1.4.3 REFRACTION TEST
9.2.1.4.4 DILATION EXAM
9.2.1.5 OTHERS
9.2.2 GENETIC DIAGNOSIS
9.3 THERAPY
9.3.1 GENE THERAPY
9.3.2 RETINAL PROSTHETIC
9.3.3 NEUROPROTECTIVE AGENTS
9.3.3.1 VITAMIN A PALMITATE
9.3.3.2 DOCOSAHEXAENOIC ACID
9.3.3.3 LUTEIN
9.3.3.4 OTHERS
9.3.4 OTHERS
10 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 SPECIALTY CLINICS
10.4 AMBULATORY SURGICAL CENTERS
10.5 HOME HEALTHCARE
10.6 OTHERS
11 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 RETAIL SALES
11.2.1 HOSPITAL PHARMACIES
11.2.2 RETAIL PHARMACIES
11.2.3 OTHERS
11.3 DIRECT TENDER
12 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY REGION
12.1 ASIA-PACIFIC
12.1.1 CHINA
12.1.2 JAPAN
12.1.3 INDIA
12.1.4 SOUTH KOREA
12.1.5 AUSTRALIA
12.1.6 SINGAPORE
12.1.7 THAILAND
12.1.8 INDONESIA
12.1.9 PHILIPPINES
12.1.10 MALAYSIA
12.1.11 VIETNAM
12.1.12 REST OF ASIA-PACIFIC
13 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 SPARK THERAPEUTICS, INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 COMPANY SHARE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENTS
15.1.4.1 PROGRAM LAUNCH
15.1.4.2 ACQUISITIONS
15.2 NOVARTIS AG
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.2.5.1 AGREEMENT
15.3 OKUVISION
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENTS
15.3.4.1 EXPANSION
15.3.4.2 EVENTS
15.3.4.3 APPROVAL
15.4 NIDEK CO., LTD
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENTS
15.4.4.1 PRODUCT LAUNCH
15.4.4.2 PRODUCT LAUNCH
15.5 INVITAE CORPORATION
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.5.5.1 PROGRAM LAUNCH
15.5.5.2 ACQUISITION
15.6 ZEISS INTERNATIONAL
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENTS
15.6.4.1 EVENTS
15.6.4.2 SOCIAL INVOLVEMENT
15.7 OPTOS (A SUBSIDIARY OF NIKON CORPORATION)
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENTS
15.8 NEUROSOFT
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 ASTELLAS PHARMA INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 BIONIC VISION TECHNOLOGIES
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.10.3.1 AWARD
15.11 COAVE THERAPEUTICS
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.11.3.1 AGREEMENT
15.12 GENSIGHT BIOLOGICS
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.12.4.1 EVENT
15.12.4.2 AWARD
15.13 IONIS PHARMACEUTICALS
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
15.13.4.1 EVENT
15.14 IVERIC BIO
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENTS
15.15 JOHNSON &JOHNSON SERVICES, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.15.4.1 COLLABORATION
15.16 LKC TECHNOLOGIES, INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.16.3.1 PRODUCT LAUNCH
15.17 MEIRAGTX LIMITED
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENTS
15.17.3.1 EVENTS
15.17.3.2 AWARD
15.17.3.3 COLLABORATION
15.18 OCUGEN INC.
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
15.18.3.1 INVESTMENT
15.18.3.2 CLINICAL TRIAL
15.19 PIXIUM VISION
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
15.19.4.1 AWARD
15.2 PROQR THERAPEUTICS
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.20.3.1 EVENT
15.21 SECOND SIGHT
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENT
15.21.3.1 PRODUCT LAUNCH
15.22 SPARING VISION
15.22.1 COMPANY SNAPSHOT
15.22.2 PRODUCT PORTFOLIO
15.22.3 RECENT DEVELOPMENT
15.22.3.1 ACQUISITION
15.23 REGENXBIO INC.
15.23.1 COMPANY SNAPSHOT
15.23.2 PRODUCT PORTFOLIO
15.23.3 RECENT DEVELOPMENTS
15.23.3.1 EVENT
15.23.3.2 COLLABORATION
15.23.3.3 CERTIFICATION
15.24 RENEURON GROUP PLC
15.24.1 COMPANY SNAPSHOT
15.24.2 PRODUCT PORTFOLIO
15.24.3 RECENT DEVELOPMENT
15.24.3.1 STRATEGIC INITIATIVE
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 PIPELINE ANALYSIS FOR INHERITED RETINAL DISEASES:
TABLE 2 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC RETINITIS PIGMENTOSA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC STARGARDT’S DISEASE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC ACHROMATOPSIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC CONE-ROD DYSTROPHY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC CHOROIDERMIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS (LCA) IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC MACULAR EDEMA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC ELECTROPHYSIOLOGICAL TETS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC THERAPY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC HOSPITALS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC SPECIALTY CLINICS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC HOME HEALTHCARE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC DIRECT TENDER IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 33 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 34 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 35 ASIA-PACIFIC THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 ASIA-PACIFIC NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 ASIA-PACIFIC DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 ASIA-PACIFIC CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 ASIA-PACIFIC RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 45 ASIA-PACIFIC RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 46 CHINA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 47 CHINA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 CHINA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 CHINA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 CHINA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 CHINA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 CHINA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 CHINA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 CHINA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 CHINA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 CHINA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 57 CHINA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 58 CHINA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 59 JAPAN INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 60 JAPAN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 JAPAN THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 JAPAN NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 JAPAN DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 JAPAN CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 JAPAN RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 JAPAN ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 JAPAN VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 JAPAN CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 JAPAN INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 JAPAN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 JAPAN RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 INDIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 73 INDIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 INDIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 INDIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 INDIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 INDIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 INDIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 INDIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 INDIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 INDIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 INDIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 83 INDIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 84 INDIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 SOUTH KOREA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 86 SOUTH KOREA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 SOUTH KOREA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 SOUTH KOREA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 SOUTH KOREA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 SOUTH KOREA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 SOUTH KOREA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 SOUTH KOREA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 SOUTH KOREA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 94 SOUTH KOREA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 SOUTH KOREA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 96 SOUTH KOREA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 97 SOUTH KOREA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 98 AUSTRALIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 99 AUSTRALIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 AUSTRALIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 AUSTRALIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 AUSTRALIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 AUSTRALIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 AUSTRALIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 AUSTRALIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 106 AUSTRALIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 AUSTRALIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 AUSTRALIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 109 AUSTRALIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 AUSTRALIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 111 SINGAPORE INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 112 SINGAPORE INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 113 SINGAPORE THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 SINGAPORE NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 SINGAPORE DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 SINGAPORE CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 117 SINGAPORE RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 SINGAPORE ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 SINGAPORE VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 SINGAPORE CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 SINGAPORE INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 122 SINGAPORE INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 123 SINGAPORE RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 124 THAILAND INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 125 THAILAND INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 126 THAILAND THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 127 THAILAND NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 THAILAND DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 THAILAND CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 THAILAND RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 THAILAND ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 132 THAILAND VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 THAILAND CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 THAILAND INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 135 THAILAND INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 136 THAILAND RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 137 INDONESIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 138 INDONESIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 INDONESIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 140 INDONESIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 141 INDONESIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 142 INDONESIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 143 INDONESIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 INDONESIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 INDONESIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 INDONESIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 INDONESIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 148 INDONESIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 149 INDONESIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 150 PHILIPPINES INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 151 PHILIPPINES INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 PHILIPPINES THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 153 PHILIPPINES NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 154 PHILIPPINES DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 155 PHILIPPINES CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 156 PHILIPPINES RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 157 PHILIPPINES ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 PHILIPPINES VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 159 PHILIPPINES CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 PHILIPPINES INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 161 PHILIPPINES INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 162 PHILIPPINES RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 163 MALAYSIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 164 MALAYSIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 165 MALAYSIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 MALAYSIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 167 MALAYSIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 168 MALAYSIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 169 MALAYSIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 170 MALAYSIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 171 MALAYSIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 MALAYSIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 173 MALAYSIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 174 MALAYSIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 175 MALAYSIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 176 VIETNAM INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 177 VIETNAM INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 VIETNAM THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 179 VIETNAM NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 180 VIETNAM DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 181 VIETNAM CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 182 VIETNAM RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 183 VIETNAM ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 184 VIETNAM VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 185 VIETNAM CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 186 VIETNAM INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 187 VIETNAM INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 188 VIETNAM RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 189 REST OF ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND EUROPE IS GROWING AT THE FASTEST PACE IN ASIA PACIFIC INHERITED RETINAL DISEASES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 INCREASE IN THE PREVALENCE OF INHERITED RETINAL DISEASES AND INCREASE IN PIPELINE PRODUCTS ARE DRIVING THE ASIA PACIFIC INHERITED RETINAL DISEASES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 RETINITIS PIGMENTOSA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC INHERITED RETINAL DISEASES MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC INHERITED RETINAL DISEASES MARKET
FIGURE 16 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, 2021
FIGURE 17 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, 2020-2029 (USD MILLION)
FIGURE 18 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 19 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY TYPE, 2021
FIGURE 21 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 22 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 23 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY END USER, 2021
FIGURE 25 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 26 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY END USER, CAGR (2022-2029)
FIGURE 27 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY END USER, LIFELINE CURVE
FIGURE 28 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 29 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 30 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 31 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET: SNAPSHOT (2021)
FIGURE 33 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2021)
FIGURE 34 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 35 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 36 ASIA-PACIFIC INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 37 ASIA PACIFIC INHERITED RETINAL DISEASES MARKET: COMPANY SHARE 2021 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
